Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:31:28.914Z.
Calculation as of: 2026-10-06T18:31:28.914Z.
Quote observation: 2026-10-06T18:30:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Galectin Therapeutics Inc.
Market Cap
$243.67M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.50M
EV/EBITDA Ratio
N/A
TTM Avg
28.93x
3Y Avg
31.09x
5Y Avg
27.66x
Market Cap
$242.12M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$237.69M
EV/EBITDA Ratio
12.82x
TTM Avg
20.89x
3Y Avg
46.57x
5Y Avg
889.74x
Market Cap
$237.27M
EV/EBITDA Ratio
N/A
TTM Avg
21.13x
3Y Avg
83.14x
5Y Avg
83.14x
Market Cap
$247.46M
EV/EBITDA Ratio
N/A
TTM Avg
70.15x
3Y Avg
225.61x
5Y Avg
165.39x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $243.67M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 28.93x | 31.09x | 27.66x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.12M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $240.16M | 6.35x | 4.45x | 4.45x | 4.45x |
| Quantum-Si incorporated (QSI)vs › | $245.30M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $239.07M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | 12.82x | 20.89x | 46.57x | 889.74x |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.27M | N/A | 21.13x | 83.14x | 83.14x |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.46M | N/A | 70.15x | 225.61x | 165.39x |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.67M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
